June 22, 2022 10:16 AM EDTUpdated 10:32 AM
R&D
FDA+

Mer­ck out­flanks Pfiz­er's 20-va­lent shot with pneu­mo­coc­cal vac­cine ap­proval for kids

Lei Lei Wu

News Reporter

Back in April, the FDA asked for more analy­sis from Mer­ck on its 15-va­lent pneu­mo­coc­cal vac­cine for chil­dren and pushed back its ap­proval dead­line by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times